Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in β-thalassemia major patients

Hemoglobin

Volumn 30, Issue 2, 2006, Pages 229-238

  Huang, Yu Chih ^a   Chang, Jeng Sheng ^a   Wu, Kang Hsi ^a   Peng, Ching Tien ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Heart failure; Iron chelator; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON CHELATING AGENT;

ADOLESCENT; ADULT; BETA THALASSEMIA; CLINICAL ARTICLE; CONFERENCE PAPER; DIASTOLE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HUMAN; IRON CHELATION; MALE; RECIPIENT; REMISSION; STUDENT T TEST; THALASSEMIA MAJOR; WILCOXON SIGNED RANKS TEST;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CARDIOMEGALY; CARDIOMYOPATHIES; CHELATION THERAPY; COHORT STUDIES; COMBINED MODALITY THERAPY; DEFEROXAMINE; DRUG EVALUATION; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEMOSIDEROSIS; HUMANS; INFANT; IRON CHELATING AGENTS; MALE; PYRIDONES; RETROSPECTIVE STUDIES; STROKE VOLUME;

EID: 33745530140     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.1080/03630260600642559     Document Type: Conference Paper

References (29)

1. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes, 3rd ed. London: Blackwell Scientific Publications, 1981.
2. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic severe refractory anemia with hemochromatosis. Circulation 1964; 30:698-705.
3. Crisaru D, Rachmilewitz EA, Mosseri M, Gotsman M, Lafair JS, Okon E, Goldfarb, A, Hasin Y. Cardiopulmonary assessment in β-thalassemia major. Chest 1990; 98(5):1138-1142.
4. Freeman AP, Giles RW, Berdoukas V, Walsh WF, Chay D, Murray PC. Early left ventricular dysfunction and chelation therapy in thalassemia. Ann Intern Med 1983; 99(4):450-454.
5. Kremastinos DT, Tontouzos PK, Vyssoulis GP, Vinitis CA, Vretan HF, Avgonstakis DG. Global and segmental left ventricular function in β-thalassemia. Cardiology 1985; 72(3):129-139.
6. Lewis BS, Rachmilewitz EA, Amitai N, Halon DA, Gotsman MS. Left ventricular function in β-thalassemia and the effect of multiple transfusions. Am Heart J 1978; 96(5):636-645.
7. Henry WL, Nienhuis AW, Wiener M, Miller DR, Canale VC, Piomelli S. Echocardiographic abnormalities in patients with transfusion-dependent anemia and secondary myocardial iron deposition. Am J Med 1978;64(4):547-555.
8. Engle SJ, DiSessa TG, Perloff JK, Isabel-Jones J, Leighton J, Gross K, Friedman WF. Mitral valve E point to ventricular septal separation in infants and children. Am J Cardiol 1983; 52(8):1084-1087.
9. Massie BM, Schiller NB, Ratshin RA, Parmley WW. Mitral-septal separation: new echocardiographic index of left ventricular function. Am J Cardiol 1977; 39(7):1008-1016.
10. Lew W, Henning H, Schelbert H, Karliner JS. Assessment of mitral valve E point-septal separation as an index of left ventricular performance in patients with acute and previous myocardial infarction. Am J Cardiol 1978; 41(5):836-845.
11. Child JS, Krivokapich J, Perloff JK. Effect of left ventricular size on mitral E point to ventricular septal separation in assessment of cardiac performance. Am Heart J 1981; 101(6):797-805.
12. Vogel M, Anderson LJ, Holden S, Deanfield JE, Pennell DJ, Walker JM.. Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload. Eur Heart J 2003; 24(1):113-119.
13. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complication of iron overload in patients with thalassemia major. N Engl J Med 1994; 331(9):567-573.
14. Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH, Nathan DG. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985; 312(25):1600-1603.
15. Kamon J, Zeuner D, Brown J, Ades AE, Wonke B, Modell B. Lifetime treatment costs of β-thalassemia major. Clin Lab Haematol 1999; 21(6):377-385.
16. Arden GB, Wonke B, Kennedy C, Huehns ER. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol 1984; 68(12):873-877.
17. Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986; 314(14):869-873.
18. Brill PW, Winchester P, Giardina PJV, Curmingham-Rundles S. Deferoxamine-induced bone dysplasia in patients with thalassemia major. Am J Roentgenol 1991; 156(3):561-565.
19. De Virgiliis S, Congia M, Frau F, Argiolu F, Diana G, Cucca F, Varsi A, Sanna G, Podda G, Fodde M. Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1988; 113(4):661-669.
20. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L. Effective chelation of iron in β thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J 1987; 295(6612):1509-1512.
21. Kontoghiorghes GJ, Aldouri MA, Sheppard I, Hoffbrand AV. 1,2-Dimethyl-3-hydroxypyrid-4-one. An orally active chelator for treatment of iron overload. Lancet 1987; 1(8545):1294-1295.
22. Vreugdenhil G, Swaak AJ, Kontoghiorghes GJ, van Eijk HG. Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients. Lancet 1989; 2(8676):1398-1399.
23. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, Nortey P. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies. Br J Haematol 1990; 76(2):295-300.
24. Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, Hirt A, Hoffbrand AV, Lottenbach AM, Sonderegger T, Wagner HP. L1 (1.2-dimethvl-3-hvdroxvpvrid-4-one) for iron chelation in patients with β-thalassaemia major. Br J Haematol 1990; 76(4):550-553.
25. Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, Puniyani RR, Chhablani AT. Long-term assessment of efficacy and safety of L1 an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992; 82(2):460-466.
26. AL-Refaie FN, Wonke B, Hoffbrand AV, Wicken DG, Nortey P, Kontoghiorghes GJ. Efficacy and possible adverse effects of the oral chelator L1 in thalassemia major. Blood 1992; 80(3):593-599.
27. Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron R, McClelland RA, Templeton DM. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992; 15(10):2741-2748.
28. Collins AF, Fassos FF, Stobie S, Lewis N, Shaw D, Fry M, Templeton DM, McClelland RA, Koren G, Olivieri NF. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994; 83(8):2329-2333.
29. Al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, Wonke B. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on oral iron chelators. Br J Haematol 1995; 91(1):224-229.